Iodamide

Summary

Iodamide (CHEMBL1201239) is an approved small-molecule radioopaque medium (ATC V08AA03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA03
• Chemistry: 627.94 Da · C12H11I3N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201239
Name	Iodamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3723
ChEBI	CHEBI:31703
ATC	V08AA03
Molecular formula	C12H11I3N2O4
Molecular weight	627.94
InChIKey	VVDGWALACJEJKG-UHFFFAOYSA-N

SMILES: CC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I

IUPAC name: 3-acetamido-5-(acetamidomethyl)-2,4,6-triiodobenzoic acid

ChEBI definition: A benzoic acid compound having iodo substituents at the 2-, 4- and 6-positions, an acetamido substituent at the 3-position and an acetamidomethyl substituent at the 5-position.

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: B-4130, Iodamida, Iodamide, Jodomiron, SH 926, SH-926, Uromiro, Uromiron, SID26748392, IODAMIDE, SID144204899, SID170465213

Parent form; salt/anhydrous children: CHEMBL1201172

Patent coverage: 506 distinct patent families (1,898 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,895 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.5	Potency	31.6	nM	CHEMBL_ACT_3651864

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).